Sacubitril/Valsartan: Neprilysin Inhibition 5 Years Later Sacubitril/Valsartan: Neprilysin Inhibition 5 Years Later

In 2014, the PARADIGM-HF trial determined that sacubitril/valsartan improved outcomes compared to enalapril in patients with chronic HFrEF. What have we learned about neprilysin inhibition since?JACC: Heart Failure
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news